The proportions of patients with high hs-CRP were 43% and 47% in the PROVE-IT (Pravastatin or Atorvastatin Evaluation and Infection Therapy) trial [14] and IMPROVE-IT (Improved Reduction of Outcomes Vytorin Efficacy International Trial) trial [15], respectively. This evidence concerns the gene CRP and infection.